サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ジェネリック無菌注射剤エコシステムの世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測
市場調査レポート
商品コード
1346838

ジェネリック無菌注射剤エコシステムの世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測

Global Generic Sterile Injectable Ecosystem Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日: | 発行: Value Market Research | ページ情報: 英文 239 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ジェネリック無菌注射剤エコシステムの世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023～2030年の予測
出版日: 2023年08月01日
発行: Value Market Research
ページ情報: 英文 239 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ジェネリック無菌注射薬エコシステム市場の世界需要は、調査期間2023～2030年のCAGR11.6%で、2022年の2,454億4,000万米ドルから2030年にはほぼ5,905億5,000万米ドルの市場規模に達すると推定されます。

ジェネリック無菌注射薬エコシステムとは、ジェネリック無菌注射薬の生産、流通、利用に関わるプロセス、市場参入企業、規制、要因の相互接続ネットワーク全体を指します。無菌注射剤は、無菌環境で調製・包装され、注射によって投与される医薬品です。これらの製品は、重篤な病気や手術を含む幅広い症状に対して、現代のヘルスケアにおいて重要な役割を果たしています。

市場力学：

重篤な疾患や手術のための注射薬に対する安定した需要が市場を活性化させています。ジェネリック無菌注射薬の費用対効果の高さは、医療の質を維持しながら経費の管理を目指すヘルスケアプロバイダーや医療システムにとって魅力的です。先発品注射剤の特許失効はジェネリック医薬品の機会を創出し、競合と低価格化を促進します。ジェネリック医薬品の承認や複雑な医薬品製造に対する規制当局の支援は、市場の成長を促します。費用対効果の高い選択肢を好むヘルスケアと、新興市場における医療インフラの拡大が、市場の拡大に寄与しています。製造技術やドラッグデリバリー技術の進歩も一役買っています。利害関係者間の協力とバイオシミラーの成長が市場をさらに形成しています。ヘルスケア政策、規制と技術の変化は市場力学に影響を与える可能性があり、業界筋からの最新の洞察の必要性を強調しています。

調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析を取り上げています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、ジェネリック無菌注射剤エコシステムの世界市場における各セグメントを包括的に評価することもできます。ジェネリック無菌注射剤エコシステム産業の成長と動向は、この研究に全体的なアプローチを提供します。

地域分析：

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東＆アフリカにおけるジェネリック無菌注射剤エコシステム市場の現在と将来の需要を強調する地域展望をカバーしています。さらに、本レポートは、すべての主要地域における個々の用途セグメントの需要、推定・予測に焦点を当てています。

ご要望がございましたら、弊社までご連絡ください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 ジェネリック無菌注射剤エコシステム分析- 産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 ジェネリック無菌注射剤エコシステムの世界市場分析：薬剤タイプ別

  • 薬剤タイプ別概要
  • 実績データと予測データ
  • 薬剤タイプ別分析
  • 抗生物質
  • 血液凝固因子
  • サイトカイン
  • 免疫グロブリン
  • インスリン
  • モノクローナル抗体
  • ペプチドホルモン
  • ワクチン

第6章 ジェネリック無菌注射剤エコシステムの世界市場分析：治療用途別

  • 治療用途別概要
  • 実績データと予測データ
  • 治療用途別分析
  • がん
  • 心血管疾患（CVD）
  • 中枢神経系
  • 糖尿病
  • 筋骨格系

第7章 ジェネリック無菌注射剤エコシステムの世界市場分析：流通チャネル別

  • 流通チャネル別概要
  • 実績データと予測データ
  • 流通チャネル別分析
  • ドラッグストア
  • 病院
  • 小売薬局

第8章 ジェネリック無菌注射剤エコシステムの世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東とアフリカ

第9章 ジェネリック無菌注射剤エコシステム企業の競合情勢

  • ジェネリック無菌注射剤エコシステム市場競争
  • 提携・協力・合意
  • 合併・買収
  • 新製品上市
  • その他の開発

第10章 企業プロファイル

  • 企業シェア分析
  • 市場集中度
  • Aspen Pharmacare Holding Ltd.
  • AuroMedics Pharma LLC
  • Cipla Pharmaceuticals Inc.
  • CSC Pharmaceuticals Inc.
  • Fresenius Kabi
  • Kay Pharma
  • Lupin Limited
  • Reddys Laboratories Limited
  • Sun Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals Inc.
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Drug Type (USD MN)
  • Antibiotics Market Sales by Geography (USD MN)
  • Blood Clotting Factors Market Sales by Geography (USD MN)
  • Cytokines Market Sales by Geography (USD MN)
  • Immunoglobulin Market Sales by Geography (USD MN)
  • Insulin Market Sales by Geography (USD MN)
  • Monoclonal Antibodies Market Sales by Geography (USD MN)
  • Peptide Hormones Market Sales by Geography (USD MN)
  • Vaccines Market Sales by Geography (USD MN)
  • Analysis Market by Therapeutic Application (USD MN)
  • Cancer Market Sales by Geography (USD MN)
  • Cardiovascular Disease (CVD) Market Sales by Geography (USD MN)
  • Central Nervous System Market Sales by Geography (USD MN)
  • Diabetes Market Sales by Geography (USD MN)
  • Musculoskeletal System Market Sales by Geography (USD MN)
  • Analysis by Distribution Channel (USD MN)
  • Drug Stores Market Sales by Geography (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Global Generic Sterile Injectable Ecosystem Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Generic Sterile Injectable Ecosystem Report
  • Market Research Process
  • Market Research Methodology
  • Global Generic Sterile Injectable Ecosystem Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Drug Type
  • Market Attractiveness Analysis by Therapeutic Application
  • Market Attractiveness Analysis by Distribution Channel
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Drug Type (USD MN)
  • Antibiotics Market Sales by Geography (USD MN)
  • Blood Clotting Factors Market Sales by Geography (USD MN)
  • Cytokines Market Sales by Geography (USD MN)
  • Immunoglobulin Market Sales by Geography (USD MN)
  • Insulin Market Sales by Geography (USD MN)
  • Monoclonal Antibodies Market Sales by Geography (USD MN)
  • Peptide Hormones Market Sales by Geography (USD MN)
  • Vaccines Market Sales by Geography (USD MN)
  • Global Market Analysis by Therapeutic Application (USD MN)
  • Cancer Market Sales by Geography (USD MN)
  • Cardiovascular Disease (CVD) Market Sales by Geography (USD MN)
  • Central Nervous System Market Sales by Geography (USD MN)
  • Diabetes Market Sales by Geography (USD MN)
  • Musculoskeletal System Market Sales by Geography (USD MN)
  • Global Market Analysis by Distribution Channel (USD MN)
  • Drug Stores Market Sales by Geography (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112112035

The global demand for Generic Sterile Injectable Ecosystem Market is presumed to reach the market size of nearly USD 590.55 BN by 2030 from USD 245.44 BN in 2022 with a CAGR of 11.6% under the study period 2023 - 2030.

The generic sterile injectable ecosystem refers to the entire interconnected network of processes, players, regulations, and factors that are involved in the production, distribution, and utilization of generic sterile injectable medications. Sterile injectables are pharmaceutical products that are prepared and packaged in a sterile environment and are administered via injection. These products play a crucial role in modern healthcare for a wide range of conditions, including critical illnesses and surgeries.

MARKET DYNAMICS:

The consistent demand for injectable medications for critical illnesses and surgeries fuels the market. The cost-effectiveness of generic sterile injectables appeals to healthcare providers and systems aiming to manage expenses while maintaining quality care. Patent expirations of brand-name injectables create opportunities for generic versions, promoting competition and affordability. Regulatory support for generic approvals and complex drug manufacturing encourages market growth. Hospitals' preference for cost-effective options and the expansion of healthcare infrastructure in emerging markets contribute to the market's expansion. Technological advancements in manufacturing and drug delivery techniques also play a role. Collaborations between stakeholders and the growth of biosimilars further shape the market. Changes in healthcare policies, regulations, and technology can impact market dynamics, highlighting the need for up-to-date insights from industry sources.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of generic sterile injectable ecosystem. The growth and trends of generic sterile injectable ecosystem industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the generic sterile injectable ecosystem market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

  • Antibiotics
  • Blood Clotting Factors
  • Cytokines
  • Immunoglobulin
  • Insulin
  • Monoclonal Antibodies
  • Peptide Hormones
  • Vaccines

By Therapeutic Application

  • Cancer
  • Cardiovascular Disease (CVD)
  • Central Nervous System
  • Diabetes
  • Musculoskeletal System

By Distribution Channel

  • Drug Stores
  • Hospitals
  • Retail Pharmacies

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Generic Sterile Injectable Ecosystem market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Generic Sterile Injectable Ecosystem market include Aspen Pharmacare Holding, Ltd., AuroMedics Pharma LLC, Cipla Pharmaceuticals, Inc., CSC Pharmaceuticals, Inc., Fresenius Kabi, Kay Pharma, Lupin Limited, Reddys Laboratories Limited, Sun Pharmaceutical Industries, Ltd., and Valeant Pharmaceuticals, Inc. among others. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . GENERIC STERILE INJECTABLE ECOSYSTEM - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Type
    • 3.7.2 Market Attractiveness Analysis By Therapeutic Application
    • 3.7.3 Market Attractiveness Analysis By Distribution Channel
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL GENERIC STERILE INJECTABLE ECOSYSTEM MARKET ANALYSIS BY DRUG TYPE

  • 5.1 Overview by Drug Type
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Drug Type
  • 5.4 Antibiotics Historic and Forecast Sales by Regions
  • 5.5 Blood Clotting Factors Historic and Forecast Sales by Regions
  • 5.6 Cytokines Historic and Forecast Sales by Regions
  • 5.7 Immunoglobulin Historic and Forecast Sales by Regions
  • 5.8 Insulin Historic and Forecast Sales by Regions
  • 5.9 Monoclonal Antibodies Historic and Forecast Sales by Regions
  • 5.10. Peptide Hormones Historic and Forecast Sales by Regions
  • 5.11 Vaccines Historic and Forecast Sales by Regions

6 . GLOBAL GENERIC STERILE INJECTABLE ECOSYSTEM MARKET ANALYSIS BY THERAPEUTIC APPLICATION

  • 6.1 Overview by Therapeutic Application
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Therapeutic Application
  • 6.4 Cancer Historic and Forecast Sales by Regions
  • 6.5 Cardiovascular Disease (CVD) Historic and Forecast Sales by Regions
  • 6.6 Central Nervous System Historic and Forecast Sales by Regions
  • 6.7 Diabetes Historic and Forecast Sales by Regions
  • 6.8 Musculoskeletal System Historic and Forecast Sales by Regions

7 . GLOBAL GENERIC STERILE INJECTABLE ECOSYSTEM MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 7.1 Overview by Distribution Channel
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Distribution Channel
  • 7.4 Drug Stores Historic and Forecast Sales by Regions
  • 7.5 Hospitals Historic and Forecast Sales by Regions
  • 7.6 Retail Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL GENERIC STERILE INJECTABLE ECOSYSTEM MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. South East Asia Sales Analysis
    • 8.5.10. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE GENERIC STERILE INJECTABLE ECOSYSTEM COMPANIES

  • 9.1. Generic Sterile Injectable Ecosystem Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF GENERIC STERILE INJECTABLE ECOSYSTEM INDUSTRY

  • 10.1. Company Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Aspen Pharmacare Holding Ltd.
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. AuroMedics Pharma LLC
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Cipla Pharmaceuticals Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. CSC Pharmaceuticals Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. Fresenius Kabi
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Kay Pharma
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. Lupin Limited
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. Reddys Laboratories Limited
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. Sun Pharmaceutical Industries Ltd.
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. Valeant Pharmaceuticals Inc.
    • 10.12.1. Company Overview
    • 10.12.2. Company Revenue
    • 10.12.3. Products
    • 10.12.4. Recent Developments
  • 10.13. Others
    • 10.13.1. Company Overview
    • 10.13.2. Company Revenue
    • 10.13.3. Products
    • 10.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies